3.0.0
679
2025-04-01T08:05:37Z
2025-04-01T08:05:37Z
House
H
HR
2025-01-23
119
[Congressional Record Volume 171, Number 14 (Thursday, January 23, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mrs. HARSHBARGER:H.R. 679.Congress has the power to enact this legislation pursuantto the following:Article I; Sec. 8 of the United States Constitution[Page H388]
- hsif00
Energy and Commerce Committee
House
Standing
  - Referred To
2025-01-23T15:08:40Z
- 2025-01-23
Referred to the House Committee on Energy and Commerce.
IntroReferral
H11100
2
House floor actions
  - hsif00
Energy and Commerce Committee
- 2025-01-23
Introduced in House
IntroReferral
Intro-H
9
Library of Congress
- 2025-01-23
Introduced in House
IntroReferral
1000
9
Library of Congress
- H001086
Rep. Harshbarger, Diana [R-TN-1]
Diana
Harshbarger
R
TN
1
N
- H001082
Rep. Hern, Kevin [R-OK-1]
Kevin
Hern
R
OK
1
2025-01-23
True
- B001295
Rep. Bost, Mike [R-IL-12]
Mike
Bost
R
IL
12
2025-01-23
True
- M001211
Rep. Miller, Mary E. [R-IL-15]
Mary
Miller
R
IL
E.
15
2025-01-23
True
- W000814
Rep. Weber, Randy K. Sr. [R-TX-14]
Randy
Weber
R
TX
K.
14
2025-01-23
True
- B001291
Rep. Babin, Brian [R-TX-36]
Brian
Babin
R
TX
36
2025-01-23
True
- M001194
Rep. Moolenaar, John R. [R-MI-2]
John
Moolenaar
R
MI
R.
2
2025-01-23
True
- W000806
Rep. Webster, Daniel [R-FL-11]
Daniel
Webster
R
FL
11
2025-01-23
True
- B001307
Rep. Baird, James R. [R-IN-4]
James
Baird
R
IN
R.
4
2025-01-23
True
- H001077
Rep. Higgins, Clay [R-LA-3]
Clay
Higgins
R
LA
3
2025-01-23
True
- F000446
Rep. Feenstra, Randy [R-IA-4]
Randy
Feenstra
R
IA
4
2025-01-23
True
- Y000067
Rep. Yakym, Rudy [R-IN-2]
Rudy
Yakym
R
IN
2
2025-01-23
True
- B001302
Rep. Biggs, Andy [R-AZ-5]
Andy
Biggs
R
AZ
5
2025-01-23
True
- P000609
Rep. Palmer, Gary J. [R-AL-6]
Gary
Palmer
R
AL
J.
6
2025-01-23
True
- G000591
Rep. Guest, Michael [R-MS-3]
Michael
Guest
R
MS
3
2025-01-23
True
- H001052
Rep. Harris, Andy [R-MD-1]
Andy
Harris
R
MD
1
2025-01-28
False
- S001224
Rep. Self, Keith [R-TX-3]
Keith
Self
R
TX
3
2025-02-04
False
- B001325
Rep. Biggs, Sheri [R-SC-3]
Sheri
Biggs
R
SC
3
2025-03-31
False
Health
- Abortion
2025-03-17T17:53:13Z
- Drug safety, medical device, and laboratory regulation
2025-03-17T17:53:30Z
- Drug therapy
2025-03-17T17:53:25Z
- Prescription drugs
2025-03-17T17:53:19Z
Health
2025-02-24T21:11:36Z
00
2025-01-23
Introduced in House
2025-03-17T21:32:05Z
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.
In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.
The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
- Official Title as Introduced
6

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
2025-02-21T11:48:33Z
Introduced in House
IH
- Display Title
45

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
2025-01-24T09:05:57Z
- Introduced in House
2025-01-23T05:00:00Z
  - https://www.govinfo.gov/content/pkg/BILLS-119hr679ih/xml/BILLS-119hr679ih.xml
2025-01-23
Referred to the House Committee on Energy and Commerce.
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
Congressional Research Service, Library of Congress
This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.